Cantor Fitzgerald set a $5.00 target price on Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note published on Monday, Marketbeat.com reports. The brokerage currently has a neutral rating on the biotechnology company’s stock.

Several other analysts also recently commented on the company. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price objective for the company in a research note on Monday, November 27th. BidaskClub raised Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, December 27th. ValuEngine raised Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, November 30th. B. Riley initiated coverage on Arrowhead Pharmaceuticals in a research note on Friday, January 5th. They set a neutral rating and a $3.00 price objective for the company. Finally, Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 16th. Five investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $4.13.

Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at $5.31 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63. Arrowhead Pharmaceuticals has a one year low of $1.42 and a one year high of $6.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.02). The company had revenue of $8.71 million for the quarter, compared to analysts’ expectations of $7.32 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 40.38%. sell-side analysts anticipate that Arrowhead Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

In other news, COO Bruce D. Given sold 20,000 shares of the stock in a transaction that occurred on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the completion of the transaction, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.60% of the company’s stock.

Several hedge funds have recently modified their holdings of ARWR. Virtu KCG Holdings LLC raised its stake in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after buying an additional 53,215 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after buying an additional 31,765 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Arrowhead Pharmaceuticals by 237.3% during the 4th quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock worth $257,000 after buying an additional 49,246 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 1,177.7% during the 4th quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock worth $264,000 after buying an additional 66,055 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $305,000. 20.48% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Arrowhead Pharmaceuticals (ARWR) Given a $5.00 Price Target by Cantor Fitzgerald Analysts” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/02/13/arrowhead-pharmaceuticals-arwr-given-a-5-00-price-target-by-cantor-fitzgerald-analysts.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.